Curis, Inc. CRIS

CRIS Company Overview

Curis, Inc. is a U.S.-based biotechnology company focused on the development of targeted therapeutics for cancer treatment. The company operates within the oncology and precision medicine sectors, with research programs centered on small molecules and immuno-oncology therapies designed to address hematologic malignancies and solid tumors. Curis generates value primarily through the clinical development of proprietary drug candidates, strategic licensing arrangements, and collaborations with larger pharmaceutical companies. Its lead programs have historically focused on signaling pathways and epigenetic targets associated with cancer progression and treatment resistance.

The company was founded in 2000 and is headquartered in Lexington, Massachusetts. Curis evolved from earlier work in developmental biology and cancer pathway research into a clinical-stage oncology company with a concentrated pipeline strategy. Over time, the company shifted from broad platform discovery efforts toward advancing internally controlled oncology assets through clinical development. Curis has also leveraged partnerships to monetize intellectual property and extend research capabilities while maintaining a relatively focused operational structure compared with larger biotechnology peers.